FGFR2 and gastric adenocarcinoma: In the dose expansion phase participant must have solid tumors with FGFR1 and/or FGFR2 gene amplified sqNSCLC, FGFR1 gene low & high amplified or gastric adenocarcinoma, including the lower esophagus/gastro-esophageal junction, FGFR2 gene low & high amplified